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Zfp521 works its zinc fingers to the bone
A 
zinc fi  nger protein controls 
two stages of bone forma-
tion by opposing the master 
regulator of osteogenesis, Hesse et 
al. report.
Runx2 is a transcription factor es-
sential for the differentiation of mesen-
chymal precursors into bone-forming 
osteoblasts. Mutations in human Runx2 
cause the skeletal disorder cleidocrani-
al dysplasia, in which certain bones are 
underdeveloped. The zinc fi  nger protein Zfp521 also controls bone 
formation and is a binding partner of Runx2. Hesse et al. examined 
how the two proteins combine to regulate osteogenesis in vivo.
Mice lacking one copy of Runx2 have underdeveloped bones 
similar to cleidocranial dysplasia patients. This phenotype was 
largely rescued by removing one copy of Zfp521, whereas overex-
pressing the zinc fi  nger protein exacerbated the bone defects. Ac-
cordingly, Hesse et al. found that Zfp521 inhibits Runx2 to limit 
the differentiation of mesenchymal cells into osteoblasts. Zfp521 
blocked Runx2 by recruiting the histone deacetylase HDAC3 to 
switch off Runx2-mediated transcription. Zfp521 was unable to 
inhibit Runx2 activity in the absence of HDAC3.
Some evidence suggests that Runx2 itself has an inhibitory 
function at later stages of bone development, preventing osteo-
blasts from reaching their fully mature state. Indeed, overexpressing 
Runx2 in adult mice resulted in reduced bone density and the accu-
mulation of immature osteoblasts. This was reversed by simultane-
ously overexpressing Zfp521, suggesting that the zinc fi  nger protein 
antagonizes Runx2 at this stage of bone development as well.
Zfp521 therefore maintains the correct balance of Runx2 ac-
tivity for osteoblast commitment and maturation. The authors now 
want to identify other transcription factors regulated by Zfp521.
Hesse, E., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201009107.
Telomeres get SIRT-ified
A 
protein that protects 
against aging-related 
diseases maintains te-
lomere length and integrity, 
Palacios et al. reveal.
Telomeres protect chromo-
some ends but grow shorter with 
age, potentially contributing to 
several age-associated illnesses. 
Budding yeast telomeres are partly maintained by a deacetylase called 
Sir2, but whether the mammalian orthologue of this protein, SIRT1, 
has a similar function is unclear. Mice overexpressing SIRT1 have an 
increased healthspan—remaining healthy for longer than wild-type 
littermates. Palacios et al. examined telomeres from these mice, as 
well as from animals that lack SIRT1 entirely.
SIRT1-defi  cient mice had shorter telomeres, whereas SIRT1 
overexpression boosted telomere length, preventing them from short-
ening as the mice grew older. This latter effect required the activity 
of telomerase enzyme, a major contributor to telomere production. 
Yet SIRT1 may also infl  uence a second maintenance pathway called 
alternative lengthening of telomeres, or ALT. SIRT1 overexpression 
increased the amount of homologous recombination at chromosome 
ends, a key step in the ALT pathway. SIRT1 boosted homologous 
recombination along the rest of chromosomes as well, suggesting 
that the deacetylase promotes DNA repair. On the other hand, SIRT1-
defi  cient cells showed increased damage at their chromosome ends.
SIRT1 therefore maintains telomere length and integrity, which 
may explain why SIRT1-overexpressing mice stay healthier for lon-
ger. Telomeres re-grow when differentiated cells are reprogrammed 
into an embryonic stem cell–like state. Palacios et al. found that SIRT1 
binds to the elongated telomeres of these induced pluripotent stem 
cells. Senior author Maria Blasco now wants to investigate whether 
SIRT1 contributes to telomere extension during reprogramming.
Palacios, J.A., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201005160.
A cell lacking SIRT1 (right) shows 
increased DNA damage (green) at 
chromosome ends (red).
Myo1 provides a ring in the tail
F
ang et al. describe two dis-
tinct pathways that target 
the tail of yeast myosin II to 
the bud neck to direct cell division.
Myosin II motors drive cy-
tokinesis by assembling a contractile 
actomyosin ring at the site of cell di-
vision. The budding yeast myosin II, 
Myo1, is targeted to the bud neck by 
its C-terminal tail, and this domain 
alone is suffi  cient to separate mother 
and daughter cells, even though it 
lacks the actin-binding and motor activity of Myo1’s head domain.
By constructing a series of deletion mutants, Fang et al. dis-
covered two separate mechanisms that localize the tail of Myo1 at 
different points in the cell cycle. Before cytokinesis, Myo1 local-
ized to the bud neck by binding Bni5, a protein that in turn binds 
to septin GTPases. During cytokinesis, however, Myo1 targeting 
depended on the actin-binding protein IQGAP instead.
The Myo1 tail was suffi  cient to assemble an actomyosin ring 
at the bud neck, perhaps because IQGAP can compensate for the 
loss of Myo1’s actin-binding head. But how does the Myo1 tail 
promote cytokinesis in the absence of any motor activity? Fang et 
al. found evidence to suggest that the “headless” actomyosin ring 
directs the deposition of vesicles around the bud neck to form the 
primary septum—a specialized cell wall region that pushes the cy-
tokinetic furrow inward. Senior author Erfei Bi says that the acto-
myosin ring therefore coordinates membrane deposition and con-
tractile force during cytokinesis. He now wants to investigate how 
Myo1 and IQGAP promote actomyosin ring assembly and how the 
ring is coordinated with septum formation.
Fang, X., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201005134.
The clavicle (arrow) is un-
derdeveloped in mice lack-
ing one copy of Runx2 (left) 
but is partially restored 
when Zfp521 expression is 
also reduced (right).
Yeast expressing the Myo1 
tail (right) still form a primary 
septum (PS), which promotes 
cytokinesis in the absence of 
Myo1 motor activity.